Wednesday, October 31, 2012

Shionogi and Janssen enter into a pact for discovery development and commercialization of BACE inhibitors for Alzheimer Disease

Shionogi  has entered into an agreement with Janssen Pharmaceuticals, for a research collaboration,  development and commercialization of oral Beta-secretase (“BACE”) inhibitors for the treatment of Alzheimer’s disease. Under the terms of this agreement, the oral BACE inhibitor compounds discovered by Shionogi, including the lead drug candidates, one of which is currently being prepared for clinical studies, will be licensed to Janssen.
After a launch of a product under this agreement, Janssen will have the right to promote it exclusively, and Shionogi shall be entitled to certain royalties. However, Shionogi holds joint promotion rights with Janssen in some territories including Japan and the USA

Enter your email address:


Delivered by FeedBurner